Role of Cholinergic Signaling in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 139 of the 141 references it cites were found in a registry or an index.
Abstract
Acetylcholine, a neurotransmitter secreted by cholinergic neurons, is involved in signal transduction related to memory and learning ability. Alzheimer’s disease (AD), a progressive and commonly diagnosed neurodegenerative disease, is characterized by memory and cognitive decline and behavioral disorders. The pathogenesis of AD is complex and remains unclear, being affected by various factors. The cholinergic hypothesis is the earliest theory about the pathogenesis of AD. Cholinergic atrophy and cognitive decline are accelerated in age-related neurodegenerative diseases such as AD. In addition, abnormal central cholinergic changes can also induce abnormal phosphorylation of ttau protein, nerve cell inflammation, cell apoptosis, and other pathological phenomena, but the exact mechanism of action is still unclear. Due to the complex and unclear pathogenesis, effective methods to prevent and treat AD are unavailable, and research to explore novel therapeutic drugs is various and active in the world. This review summaries the role of cholinergic signaling and the correlation between the cholinergic signaling pathway with other risk factors in AD and provides the latest research about the efficient therapeutic drugs and treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Second-generation AChEIs, including donepezil (4), rivastigmine (5), galantamine (6), are more selective. They exhibited fewer side effects or improved pharmacokinetic profiles, establishing them as first-line drugs for AD.98,400”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [98]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is a progressive neurodegenerative disorder and the leading cause of dementia among older adults, characterized by a gradual decline in cognitive function, memory loss, and behavioral changes, ultimately leading to complete dependence on caregivers [7].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these, neurons of the nucleus basalis of Meynert (NBM) are particularly vulnerable, and their degeneration leads to profound reductions in choline acetyltransferase (ChAT) activity within projection areas such as the cerebral cortex and hippocampus, regions essential for learning, memory, and attention [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This hypothesis suggests that a reduction in the synthesis and release of ACh impairs its physiological functions, which are critical for learning, memory, and other cognitive processes.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“The cholinergic hypothesis, one of the earliest and most influential theories of AD, proposed that the characteristic cognitive deficits of the disorder arise primarily from degeneration of cholinergic neurons in the basal forebrain [96].”
From Toward a Unified Framework in Molecular Neurobiology of Alzheimer’s Disease: Revisiting the Pathophysiological Hypotheses (2026) · cites this paper as [96]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Hafez, H. S., Ghareeb, D. A., Saleh, S. R., Abady, M. M., Demellawy, M. E., Hussien, H. M., & Abdel-Monem, N. M. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4690-x · Cited by 85
RetractedSemwal, B. C., & Garabadu, D. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08615-1 · Cited by 9 · cited 2×
“Aβ can induce mitochondrial toxicity in the brain, resulting in cognitive dysfunction [5].”
BackgroundRetractedNEUROTRANSMITTER-RELATED ENZYMES AND INDICES OF HYPOXIA IN SENILE DEMENTIA AND OTHER ABIOTROPHIES
BOWEN, D. M., SMITH, C. B., WHITE, P., & DAVISON, A. N. (1976) · Brain · doi:10.1093/brain/99.3.459 · Cited by 1,311 · cited 1×
“According to clinical data in recent years, the brains of patients with AD show severe neurodegeneration and reduction of cholinergic neurons and a severe deficiency of Ach; acetylcholine transferase activity is significantly decreased, which further illustrates the damage to the cholinergic system in patients with AD…”
BackgroundEfficacy of acetylcholinesterase inhibitors in Alzheimer’s disease.
Marucci, G., Buccioni, M., Ben, D. D., Lambertucci, C., Volpini, R., & Amenta, F. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108352 · Cited by 1,147
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Román, G. C., Jackson, R. E., Gadhia, R., Román, A. N., & Reis, J. (2019) · Revue Neurologique · doi:10.1016/j.neurol.2019.08.005 · Cited by 421
Drug candidates in clinical trials for Alzheimer’s disease
Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420
Astrogliosis: An integral player in the pathogenesis of Alzheimer's disease
Osborn, L. M., Kamphuis, W., Wadman, W. J., & Hol, E. M. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.001 · Cited by 312 · cited 1×
“AD is a major cause of dementia which is a common disease among the elderly, starting with an irreversible decline in episodic memory and then a more general decline in overall cognitive ability [2,3].”
BackgroundLiu, Y., Zhang, Y., Zheng, X., Fang, T., Yang, X., Luo, X., Guo, A., Newell, K. A., Huang, X.-F., & Yu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1141-5 · Cited by 285 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
BackgroundLuo, H., Xiang, Y., Qu, X., Liu, H., Liu, C., Li, G., Han, L., & Qin, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00395 · Cited by 264 · cited 1×
“Liposaccharide (LPS) levels are higher in the brains of Alzheimer’s patients and are associated with neuroinflammation, which is controlled by neurocholinergic signaling, and cognitive decline [81,82].”
Background
Research works printed but not linked: 1
- Yu, 2019, Protective roles of isoastilbin against Alzheimer’s disease via Nrf2mediated antioxidation and antiapoptosis, Int. J. Mol. Med., 43, 1406
Cited by
Items 101–200 of 1,000
Extract optimization of Ulva lactuca L. and biological activities of optimized extracts
Korkmaz, N. (2025) · BMC Biotechnology · doi:10.1186/s12896-025-00954-w · Cited by 24
“Inhibition of acetylcholinesterase may help improve brain functions, since increasing acetylcholine levels can improve cognitive functions such as memory and learning [42, 43].”
Kuzu, B., & Demir, Y. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110504 · Cited by 23
Kuştan, F., Sıcak, Y., Mali, S. N., Chaudhari, S. Y., Öztürk, M., & Tok, F. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143637 · Cited by 23
Türkeş, C. (2025) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2025.109259 · Cited by 23
Tokalı, F. S., Özgün, Ö., Demir, Y., Şenol, H., Acar, B., Çakır, F., & Şen, A. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.109778 · Cited by 25
Research Progress on the Pathogenesis, Diagnosis, and Drug Therapy of Alzheimer’s Disease
Yang, Y., & Qiu, L. (2024) · Brain Sciences · doi:10.3390/brainsci14060590 · Cited by 23
“Cholinergic systemic heterogeneity also promotes the accumulation of A β and the formation of neurofibrillary tangles [71].”
BackgroundPastene-Burgos, S., Muñoz, E., Quiroz‐Carreño, S., Pastene, E., Espinoza, L., Bustamante-Salazar, L. A., & Alarcón, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137303 · Cited by 23
“These processes produce a progressive reduction of the neurotransmitter acetylcholine (ACh), which produces loss of memory and cognitive deficit [11,12].”
BackgroundA Comprehensive Analysis on Galantamine Based Hybrids for the Management of Alzheimer's Disease
Singh, Y. P., Prasad, S., & Kumar, H. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70004 · Cited by 23
“AD progression is coupled with a substantial disruption of several neurotransmitters such as cholinergic, GABAergic, adrenergic, serotoninergic, and glutamatergic receptors, respectively (Chen et al. 2022).”
MiRNA-501-3p and miRNA-502-3p: a promising biomarker panel for Alzheimer’s disease
Devara, D., Sharma, B., Goyal, G., Rodarte, D., Kulkarni, A., Tinu, N., Pai, A., & Kumar, S. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70389 · Cited by 22
“4,5 Currently, no precise biomarkers or curative treatment exists for AD.”
CRISPR in Neurodegenerative Diseases Treatment: An Alternative Approach to Current Therapies
Akbar, A., Haider, R., Agnello, L., Noor, B., Maqsood, N., Atif, F., Ali, W., Ciaccio, M., & Tariq, H. (2025) · Genes · doi:10.3390/genes16080850 · Cited by 22
“It is characterized by the loss of cholinergic neurons, accumulation of intracellular neurofib-rillary tangles composed of hyperphosphorylated tau protein [67], and the presence of extracellular amyloid-beta (A β ) plaques in the brain.”
Microbial Metabolomes in Alzheimer’s Disease: From Pathogenesis to Therapeutic Potential
Borrego-Ruiz, A., & Borrego, J. J. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090724 · Cited by 22
“Clinical observations have confirmed pronounced neurodegeneration within the cholinergic system in AD, including marked reductions in ACh levels, loss of cholinergic neurons, and diminished choline acetyltransferase activity [125,222].”
Phytochemical analysis and anticholinesterase activity of aril of Myristica fragrans Houtt
Rastegari, A., Manayi, A., Rezakazemi, M., Eftekhari, M., Khanavi, M., Akbarzadeh, T., & Saeedi, M. (2022) · BMC Chemistry · doi:10.1186/s13065-022-00897-9 · Cited by 22
“Also, the role of abnormal cholinergic system in the promotion of amyloid precursor protein (APP) metabolism and tau phosphorylation which lead to neurotoxicity, neuroinflammation and neuronal death, has been proven [22].”
BackgroundSerdaroğlu, G., Uludağ, N., & Üstün, E. (2023) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2023.121364 · Cited by 22
Güngör, S. A. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14274 · Cited by 22
Kalyvas, A.-C., Dimitriou, M., Ioannidis, P., Grigoriadis, N., & Afrantou, T. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133879 · Cited by 22
“Acetylcholine is a neurotransmitter involved in memory, learning, and executive functions [4,75].”
BackgroundInfluentialPatel, P., & Shah, J. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-01086-2 · Cited by 22
Peng, L., Zhang, Z., Li, Q., Song, Z., Yan, C., & Ling, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e39217 · Cited by 21
“In addition, A β interacts with cholinergic components in various ways, including impairing cholinergic function, inhibiting the activity of ChAT and ACh, and increasing AChE activity [63].”
Yılmaz, H., & Bayraktutan, U. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040232 · Cited by 21
“ACh deficiency is therefore closely associated with the pathogenesis of Alzheimer’s disease, a form of dementia [86].”
Khan, U., Ahmad, M., Tuba, M., Naaz, R., Qayyum, F., Khatoon, S., Sanobar, Ahamad, S., Saquib, M., & Hussain, M. K. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118371 · Cited by 21
Amyloid Beta in Alzheimer's Disease: Mechanisms, Biomarker Potential, and Therapeutic Targets
Ahmadi, S., Khaledi, S., Ahmadi, K., & Hassanzadeh, K. (2025) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.70688 · Cited by 22
Digital Intervention for the Management of Alzheimer’s Disease
Manchanda, N., Aggarwal, A., Setya, S., & Talegaonkar, S. (2022) · Current Alzheimer Research · doi:10.2174/1567205020666230206124155 · Cited by 21
The Effects and Mechanisms of Xanthones in Alzheimer’s Disease: A Systematic Review
Pang, L. W., Hamzah, S. B., Tan, S. L. J., Mah, S. H., & Yow, H.-Y. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04005-8 · Cited by 21
Lutfy, R. H., Essawy, A. E., Mohammed, H. S., Shakweer, M. M., & Salam, S. A. (2023) · Neurochemical Research · doi:10.1007/s11064-023-04071-y · Cited by 21
Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects
Collins, H. M., & Greenfield, S. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25116222 · Cited by 21
“…for the loss of cholinergic neurons, drugs that enhance cholinergic transmission were developed as treatments for mild cognitive impairment (see [18]); the most common have been acetylcholinesterase (AChE) inhibitors, starting with tacrine in 1989 and now superseded by drugs such as Ari-cept…”
BackgroundRai, R., Kalar, P. L., Jat, D., & Mishra, S. K. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105799 · Cited by 21
Tirzepatide: a novel therapeutic approach for Alzheimer’s disease
Alshehri, G. H., Al-Kuraishy, H. M., Waheed, H. J., Al-Gareeb, A. I., Faheem, S. A., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01649-z · Cited by 21
“These neuropathological changes initiate microglia activation, neuroinflammation, progressive neuronal apoptosis, synaptic dysfunction, impairment of cholinergic neurotrans-mission, synaptic dysfunction, and the development of cognitive decline in AD (Chen et al. 2022) (Fig.”
Begines, P., Fernández‐Bolaños, J. G., & López, Ó. (2025) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2025.2602702 · Cited by 20
“…of neurotoxic amyloid-β plaques ( amyloid hypothesis ) [15], the presence of neurofibrillary tangles formed by hyperphosphorylation of tau protein ( tau hypothesis ) [16], and impaired neurotransmission due to reduced levels of the neurotransmitter acetylcholine ( cholinergic hypothesis ) [17].”
Akocak, S., Lolak, N., Duran, H. E., Cetinkaya, B. D., Hashem, H., Bräse, S., & Türkeş, C. (2026) · Pharmaceuticals · doi:10.3390/ph19020239 · Cited by 20
“Acetylcholine (ACh) is essential for learning and memory processes, and diminished ACh availability is closely associated with cognitive decline in AD [7,8].”
Mahdavi, K., Zendehdel, M., & Zarei, H. (2024) · Veterinary Research Communications · doi:10.1007/s11259-024-10312-4 · Cited by 20
“The cholinergic sys-tem has expanded throughout the CNS, especially the brain, and has an important role in regulating nerve function by applying its effects (Chen et al. 2022; Cetin et al. 2020).”
Cerebrovascular Dysfunction in Alzheimer’s Disease and Transgenic Rodent Models
Fang, X., Fan, F., & Roman, R. J. (2024) · Journal of Experimental Neurology · doi:10.33696/neurol.5.087 · Cited by 20
“A β and Tau accumulation in the brain is associated with reductions in cortical cholinergic function [136].”
BackgroundPOPOVICI, L.-F., Brinza, I., Gatea, F., Badea, G. I., Vamanu, E., Oancea, S., & Hriţcu, L. (2025) · Antioxidants · doi:10.3390/antiox14010097 · Cited by 20
Multi‐Targeting Phytochemicals for Alzheimer's Disease
Bhattacharya, R. S., Singh, R., Panghal, A., Thakur, A., Singh, L., Verma, R. K., Singh, C., Goyal, M., & Kumar, J. (2025) · Phytotherapy Research · doi:10.1002/ptr.8435 · Cited by 20
“AD is related with cognitive dysfunctions and loss of memory due to dysregulation of cholinergic and glutamate transmission (Chen et al. 2022).”
Amyloid-β Clearance with Monoclonal Antibodies: Transforming Alzheimer’s Treatment
Fatima, R., Khan, Y., Maqbool, M., Ramalingam, P. S., Khan, M. G., Bisht, A. S., & Hussain, M. S. (2025) · Current Protein and Peptide Science · doi:10.2174/0113892037362037250205143911 · Cited by 20
Tsimpili, H., & Zoidis, G. (2025) · Pharmaceuticals · doi:10.3390/ph18030369 · Cited by 20
“Today, AChE inhibitors are utilized as medicine to address this problem, , from [25].”
InfluentialYerraguravagari, B., Penchikala, N. P., Kolusu, A. S., Ganesh, G. S., Konduri, P., Nemmani, K. V. S., & Samudrala, P. K. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273258337230925040049 · Cited by 19
Tremendous Fidelity of Vitamin D3 in Age-related Neurological Disorders
Skv, M., Abraham, S. M., Eshwari, O., Golla, K., Jhelum, P., Maity, S., & Komal, P. (2024) · Molecular Neurobiology · doi:10.1007/s12035-024-03989-w · Cited by 20
The Role of Probiotics in Modulating the Gut Microbiome in Alzheimer’s Disease: A Review
Dong, Y., Wu, X., Zhang, Y., Hu, A., Zhou, Q., Yue, X., Liu, Z., & Li, M. (2025) · Foods · doi:10.3390/foods14091531 · Cited by 19
“Therefore, the degeneration of the BFCN in patients with AD leads to the loss of synapses between the basal forebrain and the corresponding tissues of the cortex and hippocampus, leading to a reduction in cognition, memory, and learning abilities [165].”
Schreiner, T. G., Menéndez‐González, M., & Popescu, B. O. (2022) · Biomedicines · doi:10.3390/biomedicines10071509 · Cited by 19
“One major limitation derives from the fact that some therapeutic interventions focus only on one aspect of the disease, such as limiting the neuroinflammation [19] or modulating the cholinergic system [20].”
BackgroundTiwari, P., & Tiwari, S. (2022) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2022.102824 · Cited by 20
Combination Therapy for the Treatment of Alzheimer’s Disease: Recent Progress and Future Prospects
Shirbhate, E., Patel, V. K., Tiwari, P., Kore, R., Veerasamy, R., Mishra, A., & Rajak, H. (2022) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026622666220907114443 · Cited by 18
Evaluation of Mollugo oppositifolia Linn. as cholinesterase and β-secretase enzymes inhibitor
Das, B., Bhardwaj, P. K., Sharma, N., Sarkar, A., Haldar, P. K., & Mukherjee, P. K. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.990926 · Cited by 18
“The cholinergic hypothesis is mostly considered an important factor and is neurochemically characterized by consistent interruptions in cholinergic neurotransmission which specifically affect the basal forebrain (Chen andMobley, 2019; Chen et al., 2022).”
BackgroundPuri, A. V., Mohite, P. B., Khan, S., & Singh, S. K. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101463 · Cited by 19
Recent Advances in the Search for Effective Anti-Alzheimer’s Drugs
Ogoś, M., Stary, D., & Bajda, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010157 · Cited by 18
MicroRNA-based recent research developments in Alzheimer's disease
Ramirez-Gomez, J., Dalal, S., Devara, D., Sharma, B., Rodarte, D., & Kumar, S. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241313397 · Cited by 18
Phytonutrients in Neuroprotection and Neurodegenerative Disorders
Kumar, R., Pal, O. P., Kamboj, N., & Jaiswal, A. (2025) · Current Research in Nutrition and Food Science Journal · doi:10.12944/crnfsj.13.special-issue-july.05 · Cited by 18
Alzahrani, A. Y. A., Ullah, H., Bhat, M. A., Rahim, F., Al-Wesabi, E. O., & Alanazi, T. Y. A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137167 · Cited by 18
Arıkan, F. B., Çetintaş, D., Aksoy, A., & Yıldırım, M. (2025) · Biomedicines · doi:10.3390/biomedicines13082017 · Cited by 17
“Although the pathophysiology of the disease is not yet clear, genetic predisposition and environmental factors are thought to play a role [3].”
Andrews, J. F. V., Selvaraj, D. B., Kumar, A., Roshan, S. A., Anusuyadevi, M., & Kandasamy, M. (2023) · Brain Sciences · doi:10.3390/brainsci13071108 · Cited by 17
“Remarkably, increased activity of AChE, an enzyme that hydrolyses ACh, has been linked to the pathomechanism of cognitive impairments and memory loss in various neurocognitive diseases, including AD [83,84].”
BackgroundSip, S., Rosiak, N., Sip, A., Żarowski, M., Hojan, K., & Cielecka‐Piontek, J. (2023) · Antioxidants · doi:10.3390/antiox13010024 · Cited by 18
Salari, A., Roghani, M., & Khalili, M. (2024) · Metabolic Brain Disease · doi:10.1007/s11011-024-01515-4 · Cited by 17
“Cholinergic system dysfunction is associated with mem - ory deterioration under neurotoxic conditions (Chen et al. 2022; Kamat et al. 2012).”
Mushtaq, H., Piccolella, S., Mendiola, J. A., Montero, L., Ibáñez, E., & Pacifico, S. (2025) · Foods · doi:10.3390/foods14020297 · Cited by 17
Exploring Quinazoline as a Scaffold for Developing Novel Therapeutics in Alzheimer’s Disease
Abualassal, Q. I. A., Abudayeh, Z. H. M., Sirhan, A. Y., & Mkia, A. (2025) · Molecules · doi:10.3390/molecules30030555 · Cited by 17
Khan, B., Iqbal, M. K., Khan, M. A., Khan, H. R., Kiyani, M. M., Bashir, S., & Li, S. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02337-4 · Cited by 17
Torreya grandis oil attenuates cognitive impairment in scopolamine-induced mice
Ma, J., Yuan, T., Gao, Y.-Q., Zeng, X., Liu, Z., & Gao, J. (2023) · Food & Function · doi:10.1039/d3fo03800a · Cited by 17
Rauf, A., AlMasoud, N., Ibrahim, M., Alomar, T. S., Khalil, A. A., Khursheed, T., Khan, M. U., Jan, M. S., Bhardwaj, K., Iriti, M., et al. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2905183 · Cited by 16
Naik, R. A., Rajpoot, R., Koiri, R. K., Bhardwaj, R., Aldairi, A. F., Johargy, A. K., Faidah, H. S., Babalghith, A. O., Hjazi, A. M., Alsanie, W. F., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100004 · Cited by 16
“There is a general decline in the functioning of basal forebrain neurons [ 6 ].”
Knezović, A., & Šalković‐Petrišić, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02887-2 · Cited by 15
“…from early to late time-points following STZ-icv treatment may enable comparisons with brain choliner - gic dysfunction observed at different stages of human sAD (Boller and Forette 1989 ; Rodríguez-Puertas et al. 1997; Rinne et al. 2003; Counts et al. 2007; Sultzer et al. 2022; Chen et al. 2022 ).”
Role of mitogen-activated protein kinase inhibitors in Alzheimer's disease: Rouge of brain kinases
Almasoudi, S. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Eliwa, D., Alexiou, A. T., Papadakis, M., & Batiha, G. E. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111296 · Cited by 16
Balcı, N., Aslan, K., Ertürk, A., & Gülçın, İ. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70654 · Cited by 16
“At present, there are many drug therapies targeting AChE, which is the most common therapeutic target globally (Chen et al. 2022).”
Alheety, N. F., Al‐Kubaisi, A. A., Yassin, H. A., & Alheety, M. A. (2025) · Macromolecular Symposia · doi:10.1002/masy.70156 · Cited by 16
Lee, H. L., Go, M. J., Lee, H. S., & Heo, H. J. (2024) · Antioxidants · doi:10.3390/antiox13080951 · Cited by 15
“In particular, it was confirmed that the”
Zhang, Y.-Z., Huo, D.-Y., Liu, Z., Li, X., Wang, Z., & Li, W. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118781 · Cited by 15
Chaubey, S., & Singh, L. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03515-8 · Cited by 15
“This reduction in acetylcholine is linked to cognitive deficits and neurodegenerative diseases like Alzheimer’s disease (Chen et al. 2022).”
Dahiya, M., Kumar, A., Yadav, M., & Chauhan, S. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177307 · Cited by 15
Iraji, A., Hariri, R., Hashempur, M. H., Ghasemi, M., Pourtaher, H., Saeedi, M., & Akbarzadeh, T. (2025) · BMC Chemistry · doi:10.1186/s13065-025-01475-5 · Cited by 15
Padhy, D. S., Vesmaker, K., & Banerjee, S. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114691 · Cited by 15
The potential link between the development of Alzheimer’s disease and osteoporosis
Nasme, F., Behera, J., Tyagi, P., Debnath, N., Falcone, J. C., & Tyagi, N. (2025) · Biogerontology · doi:10.1007/s10522-024-10181-z · Cited by 15
“Patients with AD exhibit degeneration of cholinergic neurons in the basal forebrain and a notable reduction in cholinergic markers, including cholineacetyl transferase and acetylcholinesterase, in the cerebral cortex (Martinez et al. 2021; Chen et al. 2022; Liu et al. 2022b; Hampel et al. 2018).”
dos Santos, A., Teixeira, F. C., da Silva, D. S., Veleda, T. A., de Mello, J. E., Luduvico, K. P., Tavares, R. G., Stefanello, F. M., Cunico, W. J., & Spanevello, R. M. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.11.015 · Cited by 14
Bridging the Binding Sites 2.0: Photoswitchable Dualsteric Ligands for the Cannabinoid 2 Receptor
Steinmüller, S. A. M., Tutov, A., Hislop, J. N., & Decker, M. W. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00509 · Cited by 14
Oyovwi, M. O., Faith, F. Y., Ejiro, O. P., Uchechukwu, J. G., Olowe, G. T., Oghenetega, O. B., Emojevwe, V. O., Edesiri, T. P., Rotu, R. A., Rotu, R. A., et al. (2023) · Brain Disorders · doi:10.1016/j.dscb.2023.100111 · Cited by 14
Pharmacological Strategies for Enzyme Inhibition in Disease Therapeutics: A Comprehensive Review
Verma, G., Bhushan, B., Singh, G., Singh, K., Kumar, S., Garg, A., & Rajput, P. (2023) · Current Enzyme Inhibition · doi:10.2174/0115734080273835231127045336 · Cited by 14
Kılıç-Kurt, Z., Konyar, D., Hayati, O. K. U. R., Kaplan, A., & Boğa, M. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.139854 · Cited by 14
Qu, L., Tang, Y. P., Wu, J., Yun, X., Lo, H. H., Song, L., Wang, X., Wang, H., Zhang, R., Liu, M., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00691-w · Cited by 14
“Acetylcholine is an important neurotransmitter in the central cholinergic system that helps individuals maintain consciousness and plays an important role in learning and memory [24].”
Dincel, E. D., Kuran, E. D., Demir, Y., Sucu, B. O., Gülçın, İ., & Ulusoy-Güzeldemirci, N. (2025) · ChemistrySelect · doi:10.1002/slct.202405876 · Cited by 14
Capsicum in Clinical Biochemistry: Insights into its Role in Health and Disease
Faisal, A. F., & Mustafa, Y. F. (2025) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-025-01317-0 · Cited by 14
Koya, P. C., Kolla, S. C., Madala, V., & Sayana, S. B. (2025) · Cureus · doi:10.7759/cureus.85814 · Cited by 14
Shoukat, S., Zia, M. A., Uzair, M., Alsubki, R. A., Sajid, K., Shoukat, S., Attia, K. A., Fiaz, S., Ali, S., Kimiko, I., et al. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08674-0 · Cited by 15
“In AD acetylcholine levels in the brain decrease significantly, which is associated with the deterioration of mental functions [15].”
BackgroundDigging into the intrinsic capacity concept: Can it be applied to Alzheimer’s disease?
López‐Ortiz, S., Caruso, G., Emanuele, E., Menéndez, H., Peñín‐Grandes, S., Guerrera, C. S., Caraci, F., Nisticò, R., Lucía, A., Santos‐Lozano, A., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102574 · Cited by 14
Afolabi, O. B., Olasehinde, O. R., Owolabi, O. V., Jaiyesimi, K. F., Adewumi, F. D., Idowu, O. T., Mabayoje, S. O., Obajuluwa, A. O., & Akpor, O. B. (2024) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-024-04424-2 · Cited by 14
“Cholinesterase play a crucial role in the hydrolysis and depletion of ACh, a neurotransmitter pivotal for cognitive and mental functions of the brain [2, 50].”
BackgroundAnusha, V. L., Yadava, S., Dontiboina, H. R., Guntupalli, C., & Ramakrishna, K. (2025) · Metabolic Brain Disease · doi:10.1007/s11011-025-01577-y · Cited by 13
“A decline in cholinergic function is primarily associated with reduced acetylcholine (ACh) levels, a neurotransmitter crucial for cognition and memory (Chen et al. 2022).”
Faryadras, K., Golchoobian, R., Iranzadeh, S., & Roghani, M. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1567236 · Cited by 13
“Additionally, abnormal cholinergic system changes provoke p-tau formation, neuronal apoptosis, and neuroinflammation, further exacerbating neurodegeneration (Chen et al., 2022).”
Ma, L., Wei, Q., Jiang, M., Wu, Y., Liu, X., Yang, Q., Bai, Z., & Yang, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136105 · Cited by 14
“Research on aging and neurodegeneration has increased its focus on the cholinergic system, particularly in the context of AD [69].”
Tariq, M., Hussain, R., Sardar, A., Rahim, F., Khan, S. A., Umer, U., Rehman, W. U., Khan, Y., Iqbal, T., Sarfraz, H., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.143418 · Cited by 13
Jung, H., Lee, Y., Lee, S., & Sohn, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020938 · Cited by 13
“Abnormalities in the cholinergic system in AD also induce abnormal amyloid precursor protein metabolism and tau phosphorylation, resulting in neurotoxicity, neuroinflammation, and apoptosis [48,49].”
Alhodieb, F. S., Rahman, M. A., Barkat, M. A., Alanezi, A. A., Barkat, H. A., Hadi, H. A., Harwansh, R. K., & Mittal, V. (2023) · Nanomedicine · doi:10.2217/nnm-2022-0108 · Cited by 13
Abdullaha, M., Banoo, R., Nuthakki, V. K., Sharma, M. K., Kaur, S., Thakur, S., Kumar, A., Jadhav, H. R., & Bharate, S. B. (2023) · ACS Omega · doi:10.1021/acsomega.2c08167 · Cited by 13
Recent Progress in the Treatment Strategies for Alzheimer’s Disease
Kumar, V., & Roy, K. (2023) · Neuromethods · doi:10.1007/978-1-0716-3311-3_1 · Cited by 13
Minocycline mitigated enduring neurological consequences in the mice model of sepsis
Hosseini, M., Bardaghi, Z., Askarpour, H., Jafari, M. M., Golkar, A., Shirzad, S., Rajabian, A., & Salmani, H. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.114856 · Cited by 13
Impact of GSK-3β and CK-1δ on Wnt signaling pathway in alzheimer disease: A dual target approach
Sharma, V., Sharma, P. C., Reang, J., Yadav, V., Tonk, R. K., Majeed, J., & Sharma, K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107378 · Cited by 12
Neuro-Adipokine Crosstalk in Alzheimer’s Disease
Chen, B., & Schneeberger, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115932 · Cited by 12
“AD is characterized by cholinergic dysfunction, resulting in a chronic state of neuronal hyperactivity [39].”
BackgroundNeuroactive Phytoconstituents of Glycyrrhiza glabra for the Treatment of Alzheimer’s Disease
Verma, M., Usman, M., & Singh, N. K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266357793241223100307 · Cited by 12
Yu, J., Cha, J., Koh, G., & Lee, I. (2025) · PLoS Biology · doi:10.1371/journal.pbio.3002702 · Cited by 12
Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD
Li, Y., Zhang, Q., Wang, X., Liu, Z., Chen, H., Xu, Y., Xu, Y., Zhang, W., Du, Y., Tan, Z., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108245 · Cited by 12
Unraveling the mystery of citrate transporters in Alzheimer’s disease: An updated review
Mukherjee, A. G., Mishra, S., Gopalakrishnan, A. V., Kannampuzha, S., Murali, R., Wanjari, U. R., Stany, B. K., Vellingiri, B., Madhyastha, H., Deepankumar, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102726 · Cited by 12
Alikhanzade, M., Khosravi, M., Hosseini, M., & Rajabian, A. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01699-w · Cited by 12
“Regret-tably, current predictions indicate that approximately 10% of the population over the age of 65 will be impacted by this disease, posing a substantial challenge for the World Health Organization (WHO) (Breijyeh and Karaman 2020; Bhatt et al. 2021; Chen et al. 2022).”
Lu, Q., Meng, Y., Feng, H., Di, X., & Guo, X. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040226 · Cited by 12
“Extensive clinical evidence demonstrates that the brains of AD patients exhibit a significant loss of cholinergic neurons and ChAT activity, along with a marked deficiency in acetylcholine [11].”
Signs of Alzheimer’s Disease: Tied to Aging
Chen, J., Zhu, Z., & Xu, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114974 · Cited by 12
“The cholinergic hypothesis states that lesions of cholinergic neurons impair ACh production and affect neuronal communication, leading to memory deficits and other cognitive deficits [84,85].”
Chauhan, P., Wadhwa, K., & Singh, G. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156109 · Cited by 12
Alzarea, S. I. (2025) · Saudi Pharmaceutical Journal · doi:10.1007/s44446-025-00026-2 · Cited by 12
“Circulating ncRNAs (e.g., miR-132, miR-206) may serve as biomarkers for monitoring AD progression or cholinesterase inhibitor responses (Kovarik et al. 2024). ncRNAs, including miRNAs, lncRNAs, and tRFs, play a crucial role in modulating cholinergic signaling in AD (Chen et al. 2022).”
Türkeş, C., Yapar, G., Duran, H. E., Lolak, N., & Akocak, S. (2026) · Future Medicinal Chemistry · doi:10.1080/17568919.2026.2617608 · Cited by 12
Metadata
- Authors
- Chen, Z.-R., Huang, J.-B., Yang, S.-L., & Hong, F.-F.
- Affiliations
- Nanchang University (CN)
- Experimental Center of Pathogen Biology, Nanchang University, Nanchang 330031, China
- Corresponding author
- Yang, Shu-Long
- Hong, Fen-Fang
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2022-03-10
- Volume
- 27
- Issue
- 6
- Pages
- 1816
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8949236
- OpenAlex
- W4220945110
- Cited by
- 922
- References
- 141
- Citations by year
- 2026: 256 · 2025: 347 · 2024: 202 · 2023: 87 · 2022: 29
- FWCI
- 22.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Natural Science Foundation of China (82060661, 81660751, 81660151)
- Jiangxi Provincial Natural Science Foundation of China (20212BAB206092)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, cholinergic neurotransmission, acetylcholine, cholinergic hypothesis, cognitive decline, tau phosphorylation, neuroinflammation, apoptosis, Alzheimer's disease pathogenesis, Alzheimer's disease therapeutics
- MeSH terms
- Acetylcholine, Alzheimer Disease, Humans, Signal Transduction, Cholinergic Agents, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.